Prognostic value of serum markers for prostate cancer
(2005) In Scandinavian Journal of Urology and Nephrology 39. p.64-81- Abstract
- The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is now the commonest cancer in males in developed countries. The increase is mainly caused by the increasing use of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in serum. With this approach, prostate cancer is detected 5-10 years before giving rise to symptoms and on average 17 years before causing the death of the patient. While this has led to detection of prostate cancer at a potentially curable stage, it has also led to substantial overdiagnosis, i.e. detection of cancers that would not surface clinically in the absence of screening. A major challenge is thus to identify the cases that... (More)
- The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is now the commonest cancer in males in developed countries. The increase is mainly caused by the increasing use of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in serum. With this approach, prostate cancer is detected 5-10 years before giving rise to symptoms and on average 17 years before causing the death of the patient. While this has led to detection of prostate cancer at a potentially curable stage, it has also led to substantial overdiagnosis, i.e. detection of cancers that would not surface clinically in the absence of screening. A major challenge is thus to identify the cases that need to be treated while avoiding diagnosing patients who will not benefit from being diagnosed and who will only suffer from the stigma of being a cancer patient. It would be useful to have prognostic markers that could predict which patients need to be diagnosed and which do not. Ideally, it should be possible to measure these markers using non-invasive techniques, i.e. by means of serum or urine tests. As it is very useful for both early diagnosis and monitoring of prostate cancer, PSA is considered the most valuable marker available for any tumor. Although the prognostic value of PSA is limited, measurement of the proportion of free PSA has improved the identification of patients with aggressive disease. Furthermore, the rate of increase in serum PSA reflects tumor growth rate and prognosis but, due to substantial physiological variation in serum PSA, reliable estimation of the rate of PSA increase requires follow-up for at least 2 years. Algorithms based on the combined use of free and total PSA and prostate volume in logistic regression and neural networks can improve the diagnostic accuracy for prostate cancer, and assays for minor subfractions of PSA and other new markers may provide additional prognostic information. Markers of neuroendocrine differentiation are useful for the monitoring of androgen-independent disease and various bone markers are useful in patients with metastatic disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/895016
- author
- Stenman, UH ; Abrahamsson, Per-Anders LU ; Aus, G ; Lilja, H ; Bangma, C ; Hamdy, FC ; Boccon-Gibod, L and Ekman, P
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- treatment, serum markers, prostate cancer, prognosis, diagnosis, follow-up
- in
- Scandinavian Journal of Urology and Nephrology
- volume
- 39
- pages
- 64 - 81
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000230568300005
- scopus:22144473007
- pmid:16019759
- ISSN
- 0036-5599
- DOI
- 10.1080/03008880510030941
- language
- English
- LU publication?
- yes
- id
- ea99bbed-3d7f-4928-b716-528d059c971d (old id 895016)
- date added to LUP
- 2016-04-01 16:58:16
- date last changed
- 2022-04-07 19:53:57
@article{ea99bbed-3d7f-4928-b716-528d059c971d,
abstract = {{The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is now the commonest cancer in males in developed countries. The increase is mainly caused by the increasing use of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in serum. With this approach, prostate cancer is detected 5-10 years before giving rise to symptoms and on average 17 years before causing the death of the patient. While this has led to detection of prostate cancer at a potentially curable stage, it has also led to substantial overdiagnosis, i.e. detection of cancers that would not surface clinically in the absence of screening. A major challenge is thus to identify the cases that need to be treated while avoiding diagnosing patients who will not benefit from being diagnosed and who will only suffer from the stigma of being a cancer patient. It would be useful to have prognostic markers that could predict which patients need to be diagnosed and which do not. Ideally, it should be possible to measure these markers using non-invasive techniques, i.e. by means of serum or urine tests. As it is very useful for both early diagnosis and monitoring of prostate cancer, PSA is considered the most valuable marker available for any tumor. Although the prognostic value of PSA is limited, measurement of the proportion of free PSA has improved the identification of patients with aggressive disease. Furthermore, the rate of increase in serum PSA reflects tumor growth rate and prognosis but, due to substantial physiological variation in serum PSA, reliable estimation of the rate of PSA increase requires follow-up for at least 2 years. Algorithms based on the combined use of free and total PSA and prostate volume in logistic regression and neural networks can improve the diagnostic accuracy for prostate cancer, and assays for minor subfractions of PSA and other new markers may provide additional prognostic information. Markers of neuroendocrine differentiation are useful for the monitoring of androgen-independent disease and various bone markers are useful in patients with metastatic disease.}},
author = {{Stenman, UH and Abrahamsson, Per-Anders and Aus, G and Lilja, H and Bangma, C and Hamdy, FC and Boccon-Gibod, L and Ekman, P}},
issn = {{0036-5599}},
keywords = {{treatment; serum markers; prostate cancer; prognosis; diagnosis; follow-up}},
language = {{eng}},
pages = {{64--81}},
publisher = {{Taylor & Francis}},
series = {{Scandinavian Journal of Urology and Nephrology}},
title = {{Prognostic value of serum markers for prostate cancer}},
url = {{http://dx.doi.org/10.1080/03008880510030941}},
doi = {{10.1080/03008880510030941}},
volume = {{39}},
year = {{2005}},
}